Sarcoidosis - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Sarcoidosis Emerging Therapy and TPP Insights

Thelansis's "Sarcoidosis Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Sarcoidosis Overview

Sarcoidosis is a multisystem granulomatous disorder of incompletely understood aetiology, characterised by the pathological accumulation of non-caseating granulomas - composed of activated macrophages, epithelioid cells, and CD4+ T-lymphocytes - in affected organs, driven by dysregulated innate and adaptive immune responses to unidentified antigenic triggers in genetically susceptible individuals. The lungs and intrathoracic lymph nodes are involved in over 90% of cases, with frequent additional involvement of skin, eyes, liver, spleen, heart, and nervous system. Patients present heterogeneously - ranging from asymptomatic incidental discovery to Lofgren syndrome, an acute, typically self-limiting presentation of bilateral hilar lymphadenopathy, erythema nodosum, and arthritis - alongside chronic dyspnoea, dry cough, fatigue, and organ-specific manifestations. Diagnosis integrates clinical, radiological, and histopathological findings; chest imaging demonstrating bilateral hilar lymphadenopathy, elevated serum ACE and sIL-2R as supportive biomarkers, and biopsy confirming non-caseating granulomas while excluding infectious and malignant mimics. Corticosteroids remain the therapeutic cornerstone for symptomatic or progressive disease, with methotrexate and azathioprine as steroid-sparing agents for chronic disease. Refractory cases may benefit from hydroxychloroquine or anti-TNF biologics including infliximab. Cardiac and neurosarcoidosis demand particularly vigilant monitoring given life-threatening complication risk. Prognosis varies considerably; spontaneous remission occurs in many, while chronic progressive disease necessitates long-term multidisciplinary surveillance and patient-centred supportive management.

Key Highlights

• In France, sarcoidosis prevalence cases are projected to increase from approximately 22,210 in 2025 to nearly 23,815 by 2035, reflecting a gradual increase in disease burden.
• Pulmonary sarcoidosis remains the predominant clinical presentation, accounting for the majority of diagnosed cases.
• Chronic progressive disease and extrapulmonary involvement continue to contribute significantly to long-term morbidity.
• Corticosteroids remain the standard of care; however, long-term steroid toxicity drives increasing use of steroid-sparing immunosuppressive therapies.
• Growing interest in targeted biologic therapies is expanding treatment options for refractory and severe sarcoidosis cases.

Market Overview

• The France sarcoidosis market is projected to grow from approximately $22 MN to $55 MN by 2035, reflecting notable market expansion.
• Market growth is supported by:
• Increasing use of immunosuppressive and biologic therapies in chronic disease management
• Improved diagnosis and long-term monitoring of multisystem disease involvement
• Market value growth is driven by prolonged treatment duration and increasing adoption of advanced therapies in refractory disease.
• Future growth will depend on development of targeted immunomodulatory therapies and improved management strategies for chronic progressive sarcoidosis.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country